Ionis Pharmaceuticals Inc
IONS80.300USD
-1.240-1.52%
終値 01/09, 16:00（ET）15分遅れの株価
12.94B時価総額
損失額直近12ヶ月PER
詳細情報 Ionis Pharmaceuticals Inc 企業名
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Incの企業情報
企業コードIONS
会社名Ionis Pharmaceuticals Inc
上場日May 17, 1991
最高経営責任者「CEO」Monia (Brett P)
従業員数1069
証券種類Ordinary Share
決算期末May 17
本社所在地2855 Gazelle Court
都市CARLSBAD
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号92010
電話番号17609319200
ウェブサイトhttps://www.ionis.com/
企業コードIONS
上場日May 17, 1991
最高経営責任者「CEO」Monia (Brett P)
Ionis Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-437.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-3241.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-8000.00%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
30.57K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.49K
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-437.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-3241.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-8000.00%
収益内訳
通貨: USD更新時刻: Tue, Mar 4
通貨: USD更新時刻: Tue, Mar 4
FY2020
FY2019
事業別USD
会社名
収益
比率
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
株主
更新時刻: Wed, Nov 19
更新時刻: Wed, Nov 19
株主統計
種類
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
他の
50.79%
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
他の
50.79%
種類
株主統計
比率
Investment Advisor
68.58%
Investment Advisor/Hedge Fund
19.53%
Hedge Fund
13.84%
Research Firm
2.62%
Pension Fund
1.04%
Bank and Trust
0.81%
Individual Investor
0.75%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
841
178.22M
110.03%
-6.52M
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Fidelity Management & Research Company LLC
23.69M
14.63%
+46.05K
+0.19%
Sep 30, 2025
Capital World Investors
17.96M
11.09%
+5.24M
+41.17%
Dec 31, 2025
The Vanguard Group, Inc.
16.44M
10.15%
-235.68K
-1.41%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
13.16M
8.12%
-2.89M
-18.02%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.45M
5.22%
-272.23K
-3.12%
Sep 30, 2025
Wellington Management Company, LLP
6.59M
4.07%
+243.03K
+3.83%
Sep 30, 2025
Bellevue Asset Management AG
6.24M
3.86%
-1.61M
-20.49%
Sep 30, 2025
State Street Investment Management (US)
4.39M
2.71%
-141.75K
-3.13%
Sep 30, 2025
Deep Track Capital LP
3.81M
2.35%
-1.08M
-22.15%
Sep 30, 2025
Two Sigma Investments, LP
3.65M
2.25%
-806.92K
-18.11%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
詳細を見る
Invesco Biotechnology & Genome ETF
比率5.24%
ARK Genomic Revolution ETF
比率4.11%
Virtus LifeSci Biotech Products ETF
比率3.34%
Franklin Genomic Advancements ETF
比率2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
比率2.57%
First Trust Health Care Alphadex Fund
比率2.47%
VanEck Morningstar SMID Moat ETF
比率2.38%
WisdomTree BioRevolution Fund
比率2.28%
State Street SPDR S&P Biotech ETF
比率2.28%
Capital Group US Small and Mid Cap ETF
比率2.04%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Ionis Pharmaceuticals Incの上位5名の株主は誰ですか？
Ionis Pharmaceuticals Incの上位5名の株主は以下のとおりです。
Fidelity Management & Research Company LLCは23.69M株を保有しており、これは全体の14.63%に相当します。
Capital World Investorsは17.96M株を保有しており、これは全体の11.09%に相当します。
The Vanguard Group, Inc.は16.44M株を保有しており、これは全体の10.15%に相当します。
T. Rowe Price Investment Management, Inc.は13.16M株を保有しており、これは全体の8.12%に相当します。
BlackRock Institutional Trust Company, N.A.は8.45M株を保有しており、これは全体の5.22%に相当します。
Fidelity Management & Research Company LLCは23.69M株を保有しており、これは全体の14.63%に相当します。
Capital World Investorsは17.96M株を保有しており、これは全体の11.09%に相当します。
The Vanguard Group, Inc.は16.44M株を保有しており、これは全体の10.15%に相当します。
T. Rowe Price Investment Management, Inc.は13.16M株を保有しており、これは全体の8.12%に相当します。
BlackRock Institutional Trust Company, N.A.は8.45M株を保有しており、これは全体の5.22%に相当します。
Ionis Pharmaceuticals Incの株主タイプ上位3種は何ですか？
Ionis Pharmaceuticals Incの株主タイプ上位3種は、
Fidelity Management & Research Company LLC
Capital World Investors
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital World Investors
The Vanguard Group, Inc.
Ionis Pharmaceuticals Inc（IONS）の株式を保有している機関の数はいくつですか？
2025Q4時点で、Ionis Pharmaceuticals Incの株式を保有している機関は841社あり、保有株式の総市場価値は約178.22Mで、全体の110.03%を占めています。2025Q3と比較して、機関の持ち株は3.25%増加しています。
Ionis Pharmaceuticals Incの最大の収益源は何ですか？
FY2020において、R&D revenue under collaborative agreements部門がIonis Pharmaceuticals Incにとって最大の収益を生み出しており、その金額は364.56Mで、全収益の49.99%を占めています。
